Galectin Therapeutics Inc.
GALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.63 | -0.18 | -0.07 | -0.15 |
| FCF Yield | -51.96% | -33.01% | -46.28% | -20.06% |
| EV / EBITDA | -4.14 | -3.82 | -2.34 | -3.69 |
| Quality | ||||
| ROIC | -1,316.98% | -302.88% | -461.35% | -92.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.80 | 0.80 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -26.70% | -6.15% | -27.76% | -17.99% |
| Safety | ||||
| Net Debt / EBITDA | -2.20 | -1.21 | -0.56 | 0.35 |
| Interest Coverage | -7.66 | -13.64 | -37.13 | -61.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -55,795.68 | -71,130.76 | -44,370.31 | -16,068.90 |